PATH | VRL
Menu

A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age

This article, published in the Journal of Infectious Diseases, reports the results of a study to evaluate the safety and immunogenicity of a recombinant respiratory syncytial virus (RSV) vaccine candidate for maternal immunization. The vaccine was found to be well tolerated, immunogenic, and reduced RSV infections, suggesting that further development is warranted. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)

Author: Glenn GM, Fries LF, Thomas DN, et al.

Published: 2016

» Visit web page (English)

(Located at jid.oxfordjournals.org)

Citation: Glenn GM, Fries LF, Thomas DN, et al. A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age. Journal of Infectious Diseases. 2016;213(3):411-422.

Resource types: Peer-reviewed journal

Diseases/vaccines: Respiratory syncytial virus (RSV)

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: North America and Europe